路透8月13日 - 美国食品药品监督管理局（FDA）周四批准了百时美施贵宝公司（Bristol Myers Squibb）的 BMY.N 联合疗法，用于治疗 患有罕见血液癌症、病情复发或对其他治疗无反应的患者 ，该监管机构表示。
路透8月13日 - 美国食品药品监督管理局（FDA）周四批准了百时美施贵宝公司（Bristol Myers Squibb）的 BMY.N 联合疗法，用于治疗 患有罕见血液癌症、病情复发或对其他治疗无反应的患者 ，该监管机构表示。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.